IRRAS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1604 SEK | -1.11% |
|
-.--% | -.--% |
| 2023 | IRRAS AB(OM:IRRAS) dropped from OMX Nordic All-Share Index | CI |
| 2023 | IRRAS AB(OM:IRRAS) dropped from OMX Nordic Small Cap Index | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -.--% | 16.67M | C | ||
| -7.58% | 10.74B | A- | ||
| +2.17% | 8.93B | C | ||
| +22.75% | 7.61B | C | ||
| +33.99% | 5.27B | B+ | ||
| +8.12% | 3.42B | C- | ||
| -8.48% | 2.86B | B- | ||
| -5.07% | 2.23B | - | - | |
| -4.22% | 2.13B | - | ||
| -20.87% | 1.84B | - | C- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
- Stock Market
- Equities
- IRRAS Stock
- Ratings IRRAS AB
